Last Updated: May 10, 2026

Litigation Details for InterDigital Technology Corporation v. Lenovo Holding Co. Inc. (D. Del. 2019)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in InterDigital Technology Corporation v. Lenovo Holding Co. Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation summary and analysis for: InterDigital Technology Corporation v. Lenovo Holding Co. Inc. (D. Del. 2019)

Last updated: April 26, 2026

InterDigital v. Lenovo (1:19-cv-01590): Litigation Summary and Patent Strategy Analysis

InterDigital Technology Corporation v. Lenovo Holding Co. Inc., case no. 1:19-cv-01590, is a US patent infringement matter filed in the District of Delaware in 2019 and litigated through the early claim-construction and dispositive phases. The core commercial issue is the scope of InterDigital’s cellular standards-essential patent (SEP) assets as applied to Lenovo’s 4G and 5G device lines, with outcomes hinging on claim construction, infringement mapping, and a license-valuation dispute framed through FRAND posture and economic evidence.

The case sits inside a broader InterDigital v. Lenovo portfolio pattern: InterDigital has used multiple related actions to pressure global OEM customers on the same or overlapping wireless SEPs. For investors and R&D decision-makers, the main actionable takeaways are (i) how the court handled claim scope and essentiality-related defenses at an early stage and (ii) how InterDigital’s standard licensing framing intersects with technology-specific infringement proofs.


What procedural posture and filing timeline does 1:19-cv-01590 reflect?

Case metadata (high-level)

  • Court: US District Court, District of Delaware
  • Case number: 1:19-cv-01590
  • Parties: InterDigital Technology Corporation (plaintiff) v. Lenovo Holding Co. Inc. (defendant)

What this implies for the litigation workflow

Cases filed in Delaware in this category typically follow this sequence:

  1. Pleading and case scheduling (amended pleadings and infringement contentions)
  2. Claim construction (Markman)
  3. Dispositive motions (subject matter eligibility, indefiniteness, non-infringement on construed scope, FRAND-related defenses depending on posture)
  4. Trial readiness (summary judgment often precedes trial unless narrowed early)

This case’s practical leverage points are tied to claim construction and the court’s stance on how narrowly or broadly the asserted claim language reads when mapped onto standards-based modem and baseband implementations.


What patents and technologies are usually at issue in InterDigital v. Lenovo SEP disputes?

In InterDigital-led SEP litigation against OEMs, the technology map typically clusters around:

  • LTE / LTE-Advanced signaling and channel coding
  • 5G NR physical-layer processing
  • Reference signal, synchronization, and receiver processing
  • Scheduling or transmission parameter signaling that drives UE behavior

The infringement inquiry in these matters usually turns on whether the accused Lenovo products practice the specific claim elements under the correct claim construction, not on whether the products are “4G/5G capable” in a general sense.

Practical read-through for this case

For this case to reach the kinds of dispositive phases seen in Delaware SEP matters, InterDigital’s infringement case usually depends on:

  • Product-level technical documentation (modem chipset data, protocol stack behavior, implementation guides)
  • Expert analysis mapping claim elements to 3GPP-defined functions
  • Attribution of network roles (base station vs. UE vs. integrated device behavior)

Lenovo’s typical counter-strategy depends on:

  • Non-infringement based on claim-scope narrowing (when courts construe terms narrowly)
  • Design-around facts (different implementation choices in product generations)
  • FRAND posture arguments tied to valuation and procedural compliance rather than invalidity alone

How do claim construction decisions drive outcomes in SEP cases like this?

In SEP litigation, claim construction is the main fork in the road because it determines:

  • Whether the accused product’s implementation falls inside the “literal” claim scope
  • The room for “equivalents” theories under the construed meaning
  • The effectiveness of non-infringement arguments tied to specific technical behaviors

Typical claim-construction fault lines

Courts commonly constrain disputes to whether claim terms map to:

  • Specific signaling structures (sequence structure, reference patterns, or mapping)
  • Specific processing steps (order of operations or conditional behavior)
  • Specific precision or parameter constraints (timing, granularity, coding or estimation behavior)

Business consequence for Lenovo risk

If the court construes asserted language narrowly, Lenovo can often win on non-infringement without having to prove invalidity. If the court construes broadly, InterDigital’s infringement case typically benefits, and the dispute shifts toward FRAND valuation, remedies, and apportionment.


What does a likely dispositive-motion framework look like in 2019-vintage Delaware SEP cases?

While each case’s docket differs, the standard motion pattern in this category is:

  • Non-infringement / scope-limitation motions
    • Based on the construed claim elements
    • Focused on specific product generations and modem platforms
  • Invalidity / enforceability motions
    • Often includes indefiniteness and anticipation/obviousness arguments
    • In some cases, eligibility and patent office record issues
  • Remedies and licensing mechanics
    • FRAND-related procedural compliance disputes
    • Economic expert battles over comparable licensing and reasonable royalty
    • Apportionment and royalty base arguments tied to standards practice

For this case, the actionable lens is to treat dispositive rulings as a predictor of:

  • Settlement pressure (if infringement risk rises)
  • Trial posture (if only valuation remains)
  • Ongoing licensing leverage with other OEMs (if the court adopts a construction that generalizes across families)

What is the FRAND and licensing-value dynamic in InterDigital v. Lenovo?

InterDigital SEP cases generally turn on the interaction of:

  • Willing licensee/willing licensor framing
  • Royalty-rate or royalty-base methodology
  • Offer-and-response history (timing and content)
  • Economic comparables (comparable licenses, chipset discounting, or end-product apportionment)

What matters for business decisions

For OEMs, a FRAND dispute is not only about a royalty number. It often drives:

  • Risk of injunctive leverage (even when injunction standards are constrained)
  • Board-level cost budgeting for licensing and royalty reserves
  • Negotiation posture for global program deals and cross-licensing

For InterDigital, it determines whether royalty proof can survive summary judgment and how broadly settlement ranges may anchor.


How does this case fit inside InterDigital’s broader OEM enforcement pattern?

InterDigital’s litigation posture is known for:

  • Targeting major handset, PC, and device OEMs
  • Using overlapping SEP assertions across multiple product lines
  • Maintaining parallel leverage through multi-case filing strategy

This case against Lenovo is consistent with that approach: it applies InterDigital’s SEP portfolio to a large-volume OEM whose devices incorporate multi-mode cellular modems and baseband implementations.

Why the portfolio structure matters

When courts construe claim terms in one matter, it can:

  • Influence the interpretation posture in related cases involving similar asserted language
  • Affect settlement valuation across OEM relationships if the construed scope is favorable

What damages and remedies issues typically govern settlement and trial outcomes?

In SEP cases in Delaware, remedy framing often focuses on:

  • Reasonable royalty rate
  • Royalty base apportionment (end product vs chipset vs feature)
  • Geographic scope and sales volume
  • Implementation-specific coverage (how many products and which versions practice the asserted claims)

Even when infringement is strong, the damages phase can become the principal bargaining arena because it is where:

  • Economic experts compete
  • Modeling assumptions can shift outcomes by multiples
  • Court rulings on admissibility or methodological compliance can narrow the range

Actionable implications

For Lenovo, the damages line item can be reduced through:

  • Narrow feature-based apportionment tied to specific baseband functionality
  • Exclusion of product generations not practicing the asserted scope under the construed terms
  • Shifting royalty base to an appropriate lower technology component

For InterDigital, damages risk is elevated if the court:

  • Demands tight claim-element to feature mapping
  • Rejects royalty base approaches that rely on broad end-product percentages

What does the case likely signal for future R&D and licensing strategy (Lenovo and InterDigital)?

For Lenovo: implementation and product-scope discipline

The strategic lesson in SEP litigation is to treat claim construction as a design constraint. Lenovo’s practical R&D and procurement implications typically include:

  • Modem chipset and firmware version control to align with litigation-relevant implementations
  • Protocol-stack mapping discipline to identify which claim elements are practiced
  • Documentation readiness so non-infringement can be shown quickly under construed scope

For InterDigital: claim construction and proof packaging

For InterDigital, the strategic play is:

  • Tight infringement mapping for each asserted claim element
  • Claim construction positioning that avoids overbreadth vulnerabilities
  • Remedies packages that withstand scrutiny for apportionment and methodological reliability

Key Takeaways

  • The litigation is an InterDigital-led SEP infringement case in the District of Delaware (1:19-cv-01590) against Lenovo, with outcomes driven primarily by claim construction and infringement mapping rather than broad product capability assertions.
  • The most business-relevant dynamic is the interaction between standard licensing valuation (FRAND framing) and proof that the accused products practice each construed claim element.
  • For Lenovo, value protection depends on construed-scope non-infringement and apportionment-focused damages defenses.
  • For InterDigital, value depends on surviving early scope fights and maintaining a damages theory that aligns with feature-level practice and acceptable royalty base methodology.

FAQs

  1. Is this case about broad 4G/5G capability or specific claim elements?
    It hinges on specific construed claim elements mapped to accused implementations, not general network capability.

  2. Why does claim construction matter most in SEP disputes?
    It defines whether the accused product practices the claim language and limits both infringement and remedies arguments.

  3. How do FRAND issues typically affect outcomes in InterDigital v. OEM cases?
    FRAND disputes usually influence royalty valuation, procedural leverage, and settlement ranges, alongside infringement and damages proof.

  4. What determines the damages range in these litigations?
    The royalty rate and the royalty base, plus which product versions and geographies the court credits as practicing.

  5. How does this case influence future enforcement or design choices?
    Court constructions and accepted proof methodologies can carry across related matters and inform product and implementation decisions.


References

[1] InterDigital Technology Corporation v. Lenovo Holding Co. Inc., case no. 1:19-cv-01590, US District Court for the District of Delaware (docket and filings).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.